Rewriting Neoadjuvant & Adjuvant HER2+ Breast Cancer Strategy -Drs. Alison Conlin & Heather McArthur

Recorded live, this in-depth conversation features Dr. Alison Conlin and Dr. Heather McArthur as they break down the evolving role of antibody–drug conjugates in early-stage HER2-positive breast cancer.

The discussion dives into DESTINY-Breast 11 and DESTINY-Breast 05, exploring how trastuzumab deruxtecan is challenging long-standing neoadjuvant and adjuvant paradigms. From pathologic complete response and invasive disease-free survival to toxicity management, ILD monitoring, and patient selection, this episode tackles how clinicians are balancing escalation and de-escalation in curative-intent care.

A thoughtful, practical conversation on where HER2-positive treatment is headed — and how today’s decisions may redefine cure for high-risk patients.